Company profile
G7 Therapeutics AG
GPCRs, a family of integral membrane proteins, are the single largest class of drug targets and linked to the pathogenesis of many diseases. The discovery of drugs targeting GPCRs has been hampered by the instability of these receptors when removed from cells. Biophysical stabilisation of GPCRs by directed evolution technologies paves the way for innovative drug discovery technologies and structure-based drug design approaches to enable the creation of novel medicines for unmet medical needs.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
